Inhibrx Biosciences, Inc.

NASDAQ:INBX

Biotechnology

Healthcare
$69.06 -2.74%

-$2.58 today

Market cap
$1.02B
Beta
3.32
P/E (TTM)
-11.0
EPS (TTM)
-$8.35
52W Low $13.97High $155.29

Volume 0.29M

Average 0.43M

INBX Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Inhibrx Biosciences, Inc.NASDAQ: INBX

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI remains negative

Q1 FY2026 Accumulated OCI was $0, compared with $0 a year earlier.

Context

  • Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Accumulated OCI vs competitors

How INBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
  • Accumulated OCI amounts to 0.0% of total assets for INBX, versus a peer median of 0.1%.
INBX Competitors
Accumulated OCI for INBX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
JANXJanux Therapeutics, Inc.Mar 2026$576K USD-84.7%—0.1%
ABSIAbsci CorporationMar 2026$304K USD+1500.0%—0.2%
GENBGenerate Biomedicines, Inc.Mar 2026$24K USD——0.0%
INBXInhibrx Biosciences, Inc.Mar 2026$0 USD——0.0%
TECXTectonic Therapeutic, Inc.Mar 2026$0 USD-100.0%—0.0%
CLDXCelldex Therapeutics, Inc.Sep 2026-$329K USD-108.7%+42.2%0.0%
IMTXImmatics N.V.Mar 2026-€6.72M EUR-300.2%—1.2%
Peer median (excluding INBX) —-100.0%+42.2%0.1%

Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents131.3M273.87M277.92M152.6M124.22M
Short-term Investments00000
Net Receivables878K257K778K420K177K
Inventory(878K)0000
Other Current Assets7.81M181K728K816K238K
Total Current Assets139.11M280.49M295.36M160.4M132.83M
Property, Plant & Equipment (Net)9.49M7.22M9.37M13.54M9.27M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.85M3.16M3.16M6.83M4.38M
Total Non-current Assets11.34M10.38M12.54M20.37M13.65M
Total Assets150.45M290.88M307.89M180.77M146.48M
Account Payables9.13M8.33M10.95M9.25M5.94M
Short-term Debt1.67M1.86M01.6M2.33M
Tax Payables00000
Deferred Revenue2.03M166K000
Other Current Liabilities9.62M13.85M6.51M7.73M18.08M
Total Current Liabilities22.45M27.58M56.31M40.73M33.8M
Long-term Debt70.47M202.07M206.97M0100.56M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)110K0000
Other Non-current Liabilities5.03M0000
Total Non-current Liabilities75.61M205.24M208.08M6.45M104.69M
Total Liabilities98.07M232.82M264.39M47.18M138.49M
Common Stock4K4K5K1K1K
Retained Earnings(227.15M)(372.37M)(613.73M)(106.13M)(246.19M)
Accumulated OCI(150.45M)0000
Other Stockholders Equity279.53M0000
Minority Interest00000
Total Equity52.38M58.06M43.5M133.58M7.99M
Total Debt72.14M207.1M210.14M8.05M107.01M
Net Debt(59.16M)(66.76M)(67.78M)(144.55M)(17.21M)

Inhibrx Biosciences, Inc.

NASDAQ:INBX

Intrinsic Alpha fair value

Locked

Current Price

$69.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.